Aarey Drugs & Pharmaceuticals Executes Warrant Conversion

11,50,000 equity shares allotted; paid-up capital increases to 3,18,74,303 shares.

Reader Takeaway: Preferential conversion strengthens cash flow but results in ongoing equity dilution for existing shareholders.

What just happened

Aarey Drugs & Pharmaceuticals Ltd has formally allotted 11,50,000 equity shares to warrant holders. This conversion, processed at Rs 47.85 per share, marks a total capital infusion of Rs 5.50 crore. The board approved the issuance on September 30, 2026, following the receipt of exercise applications.

Why this matters

For investors, this is the second tranche of warrant conversions from the issue initiated in May 2025. It reflects the company’s ongoing efforts to raise capital through its preferential issue plan. While this conversion provides necessary liquidity, it also increases the total outstanding share count, thereby adjusting earnings per share (EPS) metrics.

The backstory

The company originally issued 50,00,000 convertible warrants on May 23, 2025. Prior to this, 23,70,000 warrants were converted on August 6, 2026. Following this latest allotment, the company has successfully converted 35,20,000 warrants in total.

Risks to watch

Remaining warrants stand at 14,80,000. These instruments are eligible for conversion within an 18-month window from the initial May 2025 allotment date. Investors should monitor for further dilution as these remaining warrants are exercised, as this will continue to alter the company’s capital structure.

What to track next

Shareholders should track the remaining 14.8 lakh warrants and watch for subsequent disclosures regarding the final conversion of these instruments before the expiration deadline.